Validation of a Simple 0 to 10 Numerical Score (IBD-10) of Patient-reported Inflammatory Bowel Disease Activity for Routine Clinical Use

Inflammatory Bowel Diseases

Volumn 22, Issue 8, 2016, Pages 1902-1907

  Subramanian, Sreedhar ^a   Asher, Rebecca ^b   Weston, William ^a   Rimmer, Michael ^a   McConville, Adam ^a   Malin, Alex ^a   Jackson, Richard ^b   Collins, Paul ^a   Probert, Chris ^c   Dibb, Martyn ^a   Rhodes, Jonathan M ^c  

^a ROYAL LIVERPOOL UNIVERSITY HOSPITAL   (United Kingdom)

^b IMPERIAL CANCER RESEARCH FUND   (United Kingdom)

^c UNIVERSITY OF LIVERPOOL   (United Kingdom)

Author keywords

Crohn's disease; Harvey Bradshaw index; IBD 10; inflammatory bowel disease; patient reported outcome; simple clinical colitis activity index; ulcerative colitis

Indexed keywords

ADALIMUMAB; BECLOMETASONE; BUDESONIDE; CERTOLIZUMAB PEGOL; INFLIXIMAB; MERCAPTOPURINE; MESALAZINE; METHOTREXATE; PREDNISOLONE; C REACTIVE PROTEIN; CALGRANULIN;

ADULT; ARTICLE; CLINICAL PRACTICE; CROHN DISEASE; CROSS-SECTIONAL STUDY; DIGESTIVE SYSTEM DISEASE ASSESSMENT; DISEASE ACTIVITY; ENTERIC FEEDING; FEMALE; HARVEY BRADSHAW INDEX; HUMAN; INFLAMMATORY BOWEL DISEASE; MAJOR CLINICAL STUDY; MALE; PREDICTIVE VALUE; PRIORITY JOURNAL; PROSPECTIVE STUDY; RECEIVER OPERATING CHARACTERISTIC; REMISSION; SENSITIVITY AND SPECIFICITY; ULCERATIVE COLITIS; VALIDATION STUDY; AREA UNDER THE CURVE; BLOOD; CHEMISTRY; FECES; METABOLISM; MIDDLE AGED; SELF REPORT; SEVERITY OF ILLNESS INDEX;

ADULT; AREA UNDER CURVE; C-REACTIVE PROTEIN; COLITIS, ULCERATIVE; CROHN DISEASE; CROSS-SECTIONAL STUDIES; FECES; FEMALE; HUMANS; LEUKOCYTE L1 ANTIGEN COMPLEX; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; REMISSION INDUCTION; ROC CURVE; SELF REPORT; SEVERITY OF ILLNESS INDEX;

EID: 84979938925     PISSN: 10780998     EISSN: 15364844     Source Type: Journal    
DOI: 10.1097/MIB.0000000000000803     Document Type: Article

References (25)

1. Sandborn WJ, Feagan BG, Hanauer SB, et al. A review of activity indices and efficacy endpoints for clinical trials of medical therapy in adults with Crohn's disease. Gastroenterology. 2002;122:512-530
2. Harvey RF, Bradshaw JM. A simple index of Crohn's-disease activity. Lancet. 1980;1:514
3. Vermeire S, Schreiber S, Sandborn WJ, et al. Correlation between the Crohn's disease activity and Harvey-Bradshaw indices in assessing Crohn's disease severity. Clin Gastroenterol Hepatol. 2010;8:357-363
4. Walsh AJ, Ghosh A, Brain AO, et al. Comparing disease activity indices in ulcerative colitis. J Crohns Colitis. 2014;8:318-325
5. Schroeder KW, Tremaine WJ, Ilstrup DM. Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study. N Engl J Med. 1987;317:1625-1629
6. Danese S, Rudzinski J, Brandt W, et al. Tralokinumab for moderate-tosevere UC: a randomised, double-blind, placebo-controlled, phase IIa study. Gut. 2015;64:243-249
7. Walmsley RS, Ayres RC, Pounder RE, et al. A simple clinical colitis activity index. Gut. 1998;43:29-32
8. Gutacker N, Street A, Gomes M, et al. Should English healthcare providers be penalised for failing to collect patient-reported outcome measures? A retrospective analysis. J R Soc Med. 2015
9. Speight J, Barendse SM. FDA guidance on patient reported outcomes. BMJ. 2010;340:c2921
10. Love JR, Irvine EJ, Fedorak RN. Quality of life in inflammatory bowel disease. J Clin Gastroenterol. 1992;14:15-19
11. Irvine EJ, Zhou Q, Thompson AK. The Short Inflammatory Bowel Disease Questionnaire: a quality of life instrument for community physicians managing inflammatory bowel disease. CCRPT Investigators. Canadian Crohn's Relapse Prevention Trial. Am J Gastroenterol. 1996;91:1571-1578
12. Czuber-Dochan W, Norton C, Bassett P, et al. Development and psychometric testing of inflammatory bowel disease fatigue (IBD-F) patient selfassessment scale. J Crohns Colitis. 2014;8:1398-1406
13. Reilly MC, Gerlier L, Brabant Y, et al. Validity, reliability, and responsiveness of the work productivity and activity impairment questionnaire in Crohn's disease. Clin Ther. 2008;30:393-404
14. Allen PB, Kamm MA, Peyrin-Biroulet L, et al. Development and validation of a patient-reported disability measurement tool for patients with inflammatory bowel disease. Aliment Pharmacol Ther. 2013;37:438-444
15. Vande Casteele N, Khanna R, Levesque BG, et al. The relationship between infliximab concentrations, antibodies to infliximab and disease activity in Crohn's disease. Gut. 2014
16. Dhaliwal A, Zeino Z, Tomkins C, et al. Utility of faecal calprotectin in inflammatory bowel disease (IBD): what cut-offs should we apply? Frontline Gastroenterol. 2015;6:14-19
17. Bassi A, Dodd S, Williamson P, et al. Cost of illness of inflammatory bowel disease in the UK: a single centre retrospective study. Gut. 2004; 53:1471-1478
18. Kappelman MD, Rifas-Shiman SL, Porter CQ, et al. Direct health care costs of Crohn's disease and ulcerative colitis in US children and adults. Gastroenterology. 2008;135:1907-1913
19. Bodger K, Ormerod C, Shackcloth D, et al. Development and validation of a rapid, generic measure of disease control from the patient's perspective: the IBD-control questionnaire. Gut. 2014;63:1092-1102
20. Wilcox AR, Dragnev MC, Darcey CJ, et al. A new tool to measure the burden of Crohn's disease and its treatment: do patient and physician perceptions match? Inflamm Bowel Dis. 2010;16:645-650
21. van Langenberg DR, Gibson PR. Factors associated with physical and cognitive fatigue in patients with Crohn's disease: a cross-sectional and longitudinal study. Inflamm Bowel Dis. 2014;20:115-125
22. Theede K, Holck S, Ibsen P, et al. Level of fecal calprotectin correlates with endoscopic and histologic inflammation and identifies patients with mucosal healing of ulcerative colitis. Clin Gastroenterol Hepatol. 2015
23. Schoepfer AM, Beglinger C, Straumann A, et al. Fecal calprotectin correlates more closely with the Simple Endoscopic Score for Crohn's disease (SES-CD) than CRP, blood leukocytes, and the CDAI. Am J Gastroenterol. 2010;105:162-169
24. Sipponen T, Savilahti E, Kolho KL, et al. Crohn's disease activity assessed by fecal calprotectin and lactoferrin: correlation with Crohn's disease activity index and endoscopic findings. Inflamm Bowel Dis. 2008;14: 40-46
25. Boon GJ, Day AS, Mulder CJ, et al. Are fecal markers good indicators of mucosal healing in inflammatory bowel disease? World J Gastroenterol. 2015;21:11469-11480